問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taichung Veterans General Hospital

List

1346Cases

2025-03-01 - 2032-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    Frozen crystal powder for injection Injection

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2032-01-31

Phase II/III

Active
A phase 2/3, open-label, randomized trial evaluating the efficacy of telisotuzumab adizutecan monotherapy versus osimertinib in patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who have progressed after third-generation EGFR TKI therapy, compared with standard of care. - AndroMETa-Lung-713

  • Condition/Disease

    Subjects with locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after third-generation EGFR TKI treatment

  • Test Drug

    Telisotuzumab Adizutecan (ABBV-400)

Participate Sites
8Sites

Recruiting8Sites

2025-10-01 - 2028-12-31

Active
A phase 2b, randomized, double-blind, placebo-controlled, parallel, multiple-dose trial was conducted to evaluate the efficacy, safety, and pharmacokinetics of AZD0292 in patients aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa grafts.

  • Condition/Disease

    In NCFBE and chronic PsA transfer subjects, the effect of AZD0292 IV every 4 weeks (Q4W) compared with placebo on the incidence of moderate to severe acute lung exacerbations was evaluated.

  • Test Drug

    AZD0292

Participate Sites
7Sites

Recruiting7Sites

2025-09-23 - 2028-02-13

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    Film-coated tablets Film-coated tablets

Participate Sites
8Sites

Recruiting8Sites

2025-10-31 - 2029-06-26

Not yet recruiting
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy and safety of Verekitug (UPB-101) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).

  • Condition/Disease

    Moderate to severe chronic obstructive pulmonary disease (COPD)

  • Test Drug

    UPB-101

Participate Sites
8Sites

Not yet recruiting8Sites

2025-10-01 - 2034-05-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

  • Condition/Disease

    Cervical Cancer

  • Test Drug

    Injectables Injectables Injectables

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

  • Condition/Disease

    Focal Segmental Glomerulosclerosis

  • Test Drug

    Film-coated tablets Film-coated tablets

Participate Sites
9Sites

Recruiting9Sites

2025-11-01 - 2033-12-31

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

  • Condition/Disease

    Endometrial Cancer

  • Test Drug

    Cryocrystalline injection Intravenous infusion Intravenous infusion Intravenous infusion Intravenous infusion

Participate Sites
5Sites

Not yet recruiting5Sites

2025-11-01 - 2030-12-31

Phase II

Active
A phase 2b/3, randomized, double-blind, placebo-controlled, multicenter trial was conducted to investigate the efficacy and safety of lunsekimig in adult subjects with poorly controlled chronic obstructive pulmonary disease (COPD) of the eosinophilic leukocytosis phenotype.

  • Condition/Disease

    The efficacy of lunsekimig was assessed by measuring the annualized incidence of moderate to severe COPD exacerbations.

  • Test Drug

    Lunsekimig/ SAR443765

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2025-11-01 - 2030-05-18

Phase III

Active
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    Frozen crystal powder for injection Intravenous infusion solution Infusion solution Infusion solution Concentrated powder Infusion solution

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4 5 135
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB